



Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

TRANSMITTAL FORM

(to be used for all correspondence after initial filing)

Total Number of Pages in This Submission

6

Application Number

10/602,441

Filing Date

June 24, 2003

First Named Inventor

Anish Sen Majumdar, et al.

Art Unit

1632

Examiner Name

Anoop Kumar Singh

Attorney Docket Number

086/002

ENCLOSURES (Check all that apply)



Fee Transmittal Form (in duplicate)



Fee Attached



Amendment/Reply



After Final



Affidavits/declaration(s)



Extension of Time Request



Express Abandonment Request



Information Disclosure Statement
(2 pages)



Certified Copy of Priority
Document(s)



Reply to Missing Parts/
Incomplete Application



Reply to Missing Parts
under 37 CFR 1.52 or 1.53



Drawing(s)



Licensing-related Papers



Petition



Petition to Convert to a
Provisional Application



Power of Attorney, Revocation



Change of Correspondence Address



Terminal Disclaimer



Request for Refund



CD, Number of CD(s) _____

☐ Landscape Table on CD



After Allowance Communication to TC



Appeal Communication to Board
of Appeals and Interferences



Appeal Communication to TC
(Appeal Notice, Brief, Reply Brief)



Proprietary Information



Status Letter



Other Enclosure(s) (please identify
below):

Remarks

1. PTO Form 1449 (1 pages) with copies of 9 references
2. Return Receipt Postcard

SIGNATURE OF APPLICANT, ATTORNEY, OR AGENT

Firm Name

Geron Corporation

Signature

Bart W. Wise

Printed name

Bart W. Wise,

Date

Dec 18, 2006

Reg. No.

49,029

CERTIFICATE OF TRANSMISSION/MAILING

I hereby certify that this correspondence is being facsimile transmitted to the USPTO or deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450 on the date shown below:

Signature

Helen A. Jackson

Typed or printed name


Helen A. Jackson

Date

Dec 18, 2006

This collection of information is required by 37 CFR 1.5. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.11 and 1.14. This collection is estimated to 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.



PTO/SB/17 (07-06)

Approved for use through 01/31/2007. OMB 0651-0032

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995 no persons are required to respond to a collection of information unless it displays a valid OMB control number

Effective on 12/08/2004.

Fees pursuant to the Consolidated Appropriations Act, 2005 (H.R. 4818).

FEE TRANSMITTAL

For FY 2005

☐ Applicant claims small entity status. See 37 CFR 1.27

TOTAL AMOUNT OF PAYMENT (\$) 180.

Complete if Known

Application Number	10/602,441
Filing Date	June 24, 2003
First Named Inventor	Anish Sen Majumdar et al.
Examiner Name	Anoop Kumar Singh
Art Unit	1632
Attorney Docket No.	086-002

METHOD OF PAYMENT (check all that apply)

☐ Check ☐ Credit Card ☐ Money Order ☐ None ☐ Other (please identify): _____

☒ Deposit Account Deposit Account Number: 07-1139 Deposit Account Name: Geron Corporation

For the above-identified deposit account, the Director is hereby authorized to: (check all that apply)

☒ Charge fee(s) indicated below ☐ Charge fee(s) indicated below, except for the filing fee

☒ Charge any additional fee(s) or underpayments of fee(s) under 37 CFR 1.16 and 1.17 ☒ Credit any overpayments

WARNING: Information on this form may become public. Credit card information should not be included on this form. Provide credit card information and authorization on PTO-2038.

FEE CALCULATION**1. BASIC FILING, SEARCH, AND EXAMINATION FEES**

Application Type	FILING FEES		SEARCH FEES		EXAMINATION FEES		Fees Paid (\$)
	Fee (\$)	Small Entity Fee (\$)	Fee (\$)	Small Entity Fee (\$)	Fee (\$)	Small Entity Fee (\$)	
Utility	300	150	500	250	200	100	
Design	200	100	100	50	130	65	
Plant	200	100	300	150	160	80	
Reissue	300	150	500	250	600	300	
Provisional	200	100	0	0	0	0	

2. EXCESS CLAIM FEES**Fee Description**

Each claim over 20 (including Reissues)
Each independent claim over 3 (including Reissues)
Multiple dependent claims

	Small Entity Fee (\$)
Each claim over 20 (including Reissues)	50
Each independent claim over 3 (including Reissues)	200
Multiple dependent claims	360

Multiple Dependent Claims

Fee (\$)	Fee Paid (\$)

Total Claims **Extra Claims** **Fee (\$)** **Fee Paid (\$)**

_____ - 20 or HP = _____ x _____ = _____

HP = highest number of total claims paid for, if greater than 20.

Indep. Claims **Extra Claims** **Fee (\$)** **Fee Paid (\$)**

_____ - 3 or HP = _____ x _____ = _____

HP = highest number of independent claims paid for, if greater than 3.

3. APPLICATION SIZE FEE

If the specification and drawings exceed 100 sheets of paper (excluding electronically filed sequence or computer listings under 37 CFR 1.52(e)), the application size fee due is \$250 (\$125 for small entity) for each additional 50 sheets or fraction thereof. See 35 U.S.C. 41(a)(1)(G) and 37 CFR 1.16(s).

Total Sheets	Extra Sheets	Number of each additional 50 or fraction thereof	Fee (\$)	Fee Paid (\$)
_____	_____	_____	_____	_____

_____ - 100 = _____ / 50 = _____ (round up to a whole number) x _____ = _____

4. OTHER FEE(S)

Non-English Specification, \$130 fee (no small entity discount)

Other (e.g., late filing surcharge): IDS fee

Fees Paid (\$)

\$180

SUBMITTED BY

Signature	<u>Bart W. Wise</u>	Registration No. (Attorney/Agent)	49,029	Telephone	(650) 473-7753
Name (Print/Type)	Bart W. Wise	Date	Dec 15, 2006		

This collection of information is required by 37 CFR 1.136. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 30 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.



PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In the application of: Anish Sen Majumdar, *et al.*

Art Unit: 1632

Serial No.: 10/602,441

Examiner: Anoop Kumar Singh

Filing Date: June 24, 2003

Attorney Docket: 086/002

For: CANCER VACCINES CONTAINING
XENOGENEIC EPITOPES OF TELOMERASE
REVERSE TRANSCRIPTASE

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

Mail Stop: Amendment
Commissioner for Patents
P. O. Box 1450
Arlington, VA 22313-1450

Dear Sir:

The information listed in the accompanying form PTO-1449 and provided herewith may be material to examination of this application and is submitted in compliance with the duty of disclosure under 37 CFR § 1.56. The Examiner is requested to make this information of record in the application.

This Information Disclosure Statement is not to be construed as a representation that a full search for relevant information has been made, that all relevant information has been found, or that the information provided with this Statement is considered to be material to patentability of the claimed invention as defined under 37 CFR § 1.56(b).


12/27/2006 JADD01 00000046 071139 10602441

01 FC:1806 180.00 DA

This Information Disclosure Statement is being filed after the first Office Action on the merits, but before issuance of a final Office Action or Notice of Allowance, pursuant to 37CFR § 1.197(c)(2). Authorization to charge Deposit Account 07/1139 (Ref.: 086/002) with the fee therefore under 37 CFR § 1.117(p) is provided in the accompanying fee calculation sheet.

Should any other fees be required for further consideration of the application and the enclosed information, the Commissioner is hereby authorized to charge such fees (or credit any overpayment) to the Deposit Account.

Respectfully submitted,




Bart W. Wise
Registration No. 49,029

GERON CORPORATION
230 Constitution Drive
Menlo Park, CA 94025
Telephone: (650) 473-7753
Fax: (650) 473-8654

December 15, 2006

Form 1449 (modified) Supplemental Information Disclosure Statement By Applicant Page 1 of 1	Filing Date: June 24, 2003	U.S.S.N. 10/602,441
	Inventors: Anish Majumdar et al.	Docket: 086/002
	Title: Cancer Vaccines Containing Xenogeneic Epitopes of Telomerase Reverse Transcriptase	
	Group: 1632	Examiner: Anoop Kumar Singh



U.S. Patent Documents

Examiner Initial	Ref.	Patent No.	Issue or Pub Date	Inventors:	Assignee:	Title:
	BF	2003/0143228	Jul 31-2003	Chen et al.		

Foreign Patents and Published Foreign Patent Applications

Examiner Initial	Ref.	Jurisdiction	Document No.	Publication Date	Assignee:	Title:	Translation
	BG	PCT	WO 99/27113 A	Jun 3, 1999	Geron Corporation		
	BH	PCT	WO 00/46355 A	Aug 10, 2000	Geron Corporation		

Other Documents

Examiner Initial	Ref.	Author, Title, Source, Date
	BI	LU ET AL.; "Immunogene Therapy of Tumors with Vaccine Based on Xenogeneic Epidermal Growth Factor Receptor"; Journal of Immunology, 2003, 170: 3162-3170.
	BJ	SIOUD ET AL.; "Generation of an Effective Anti-Tumor Immunity After Immunization with Xenogeneic Antigens"; Eur. J. Immunol. 2003.33:38-45.
	BK	SRINIVASAN ET AL.; "Tumor Antigens for Cancer Immunotherapy; Therapeutic Potential of Xenogeneic DNA Vaccines"; Journal of Translational Medicine 2004, 2:12.
	BL	SU ET AL.; "Telomerase mRNA – Transfected Dendritic Cells Stimulate Antigen-Specific CD8+ and CD4+ T Cell Responses in Patients with Metastatic Prostate Cancer"; The Journal of Immunology, 2005, 174: pp 3798-3807.
	BM	TAN ET AL.; "Combination of Low-Dose Cisplatin and Recombinant Xenogeneic Endoglin as a Vaccine Induces Synergistic Antitumor Activities"; Int. J. Cancer: 112, 701-706 (2004).
	BN	TAN ET AL.; "Active Immunotherapy of Tumors with a Recombinant Xenogeneic Endoglin as a Model Antigen"; Eur. J. Immunol. 2004. 34:2012-2021.

Examiner	Date Considered
----------	-----------------

Examiner: Initial if citation considered, whether or not citation is in conformance with MPEP § 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.